Cannabis News

cheap wholesale shatter canada

Phyto Extractions Launches New Shatter Product Line to Canadian Retail Market in Time for 420

Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(Frankfurt:D2EP) ("Phyto Extractions™" or the "Company") is proud to announce the launch of three new Shatter Products, adding to its product line in the burgeoning cannabis extracts market

About Shatter Products

A favourite among Cannabis enthusiasts, Phyto Extractions'™ shatter product line launches with three of the most popular cannabis strain extracts on the market through its one gram offerings; Pink Kush, Blueberry Gorilla and Death Bubba.

Phyto Extractions'™ current increasing market share in the disposable vape, vape cartridge and live resin markets, strengthens the brands launch of its new flagship shatter product line. With relatively few players in the shatter product space in Canada, this expansion represents a significant opportunity given the forecasted growth of the Cannabis extract market.

Staying true to the corporate mission of being: "...a cannabis brand grown from its legacy roots as the first real name in extracts to deliver the experience of quality and value through all of our product offerings." Phyto Extractions will be pricing its products to strive to be the lowest priced in every market served in the specific formats offered.

"Our goal is not only to serve existing cannabis enthusiasts with the quality and value they demand," said David Kolby, VP of Marketing. "Our strategy is to send a signal to black market consumers as well, that there are legal market players that want their business and are willing to do what it takes to attract them to the legal market with safe and competitive product offerings."

The Shatter products will be launched in British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario with the rest of Canada to follow soon thereafter, in addition to new shatter products that are in development.

About Phyto Extractions™

Phyto Extractions™ is an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.

ON BEHALF OF THE BOARD
Adastra Labs HOLDINGS LTD.

Contact: J. Scott Munro, President, CEO & Director (Chairman)
Phone: (778) 715-5011
Email: scott@adastralabs.ca

Forward-Looking Information:

This news release includes forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking information in this news release includes statements with respect of the proposed name change, proposed consolidation, the closing of the private placement and the use of proceeds thereof. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the cannabis extraction sector in general; (iii) inability to close the private placement for any reason, or in the amounts expected by the Company; and (iv) other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

The CSE has not reviewed or approved of any contents of this news release.

SOURCE: Phyto Extractions Inc.



View source version on accesswire.com:
https://www.accesswire.com/639723/Phyto-ExtractionsTM-Adastra-Labs-Launches-New-Shatter-Product-Line-to-Canadian-Retail-Market-in-Time-for-420

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Creso Pharma

Wholly-Owned Subsidiary, Mernova Medicinal Inc. Continues Strong Progress In Q2 Securing C$593,926 In New Purchase Orders During May

Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to provide the following update on progress through wholly-owned Canadian subsidiary, Mernova Medicinal Inc. (‘Mernova’), which has continued to achieve strong growth in purchase orders in May, as well as an extension of licenses with Health Canada and Canada Revenue Agency.

Keep reading...Show less

Trulieve Announces Opening of Affiliated Medical Marijuana Dispensary in Limerick, PA

New dispensary expands patient access to medical cannabis with ribbon cutting and pop-up event

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the grand opening of a new Trulieve-affiliated medical marijuana dispensary in Limerick, PA. Located at 451 West Ridge Pike, the doors will open 9 AM on Friday, May 19 2023 with ongoing hours of 9 AM - 10 PM seven days a week.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
  Creso Pharma

Creso Pharma Secures Firm Commitments To Raise $2.5M, Extends Secured Notes And Streamlines Balance Sheet With Debt To Equity Conversions

Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise that it has secured firm commitments from institutional, professional and sophisticated investors to raise $2.5m million (before costs) through the issue of 204,918,033 new fully paid ordinary shares (“Shares”) at an issue price of $0.0122 per Share (the “Placement”). As well, the Company has converted a number of current liabilities to equity, agreed to repay convertible notes to Obsidian Global GP, LLC (“Obsidian”) and agreed in principle to extend its existing Secured Notes with investors.

Keep reading...Show less

Goodness Growth Holdings Announces First Quarter 2023 Results

Q1 revenue of $19.1 million increased 22.1% YoY and 30.5% excluding discontinued operations –

– Cost controls and operational improvements drive second consecutive quarter of positive income from operations –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Speak at the Canaccord Genuity 7th Annual Global Cannabis Conference

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the Canaccord Genuity 7 th Annual Global Cannabis Conference on Thursday, May 18, 2023, at 11:00AM ET.

A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×